Search papers, labs, and topics across Lattice.
The paper introduces MEGA-CL, a novel graph neural network framework designed for accurate ADMET prediction of small molecules in drug discovery. By integrating self-supervised contrastive learning with a multi-head external attention mechanism, MEGA-CL effectively captures both local chemical substructures and global inter-graph relationships, overcoming the over-smoothing issues typical in deep graph networks. The model achieves clinically relevant predictive accuracy across 13 benchmark datasets, with over 75% of predictions falling within a 3-fold error range, and demonstrates strong generalization in external validations, making it a promising tool for in silico ADMET evaluation.
MEGA-CL achieves over 75% accuracy in ADMET predictions, significantly outperforming existing models and showcasing its potential for accelerating drug discovery.
Predicting the absorption, distribution, metabolism, excretion and toxicity (ADMET) properties of small molecules remains a major challenge in drug discovery. Here, we present MEGA-CL, a foundation graph neural network framework for universal molecular ADMET prediction. MEGA-CL integrates self-supervised contrastive learning with a multi-head external attention mechanism and an enhanced message-passing architecture, enabling simultaneous modeling of local chemical substructures and global inter-graph relationships while mitigating over-smoothing effects commonly observed in deep graph networks. Across 13 benchmark datasets and 21 downstream ADMET tasks, MEGA-CL consistently outperforms state-of-the-art baseline models. In particular, the framework demonstrates robust performance on challenging regression tasks, including clearance (CL) and steady-state volume of distribution (VDss), while maintaining strong generalization ability in independent external validation. Clinically relevant predictive accuracy was achieved, with more than 75% of predictions falling within a 3-fold error range. In an external evaluation on 18 novel compounds derived from recently approved FDA drugs, over 50% of human liver microsome clearance (HLMC) predictions were within a 2-fold error range. To further assess its practical applicability, MEGA-CL was prospectively evaluated on three preclinical drug candidates using in vitro hepatic microsomal metabolism assays and CYP450 inhibition assays guided by model predictions. The predicted HLMC values for all candidates were within 2.5-fold of the experimentally measured values, and 73.3% of CYP450 inhibition endpoints (11/15) were correctly classified. These results demonstrate the potential of MEGA-CL as a generalizable framework for accelerating in silico ADMET evaluation and early-stage drug candidate optimization.
